For the third quarter of the fiscal year ending March 2026, net sales were \u00a587,487 million (up 8.4% YoY), operating income was \u00a57,526 million (up 3.9% YoY), and net income attributable to owners of parent was \u00a56,342 million (up 13.2% YoY), demonstrating steady business performance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4534-20260206-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, net sales were \u00a587,487 million (up 8.4% YoY), operating income was \u00a57,526 million (up 3.9% YoY), and net income attributable to owners of parent was \u00a56,342 million (up 13.2% YoY), demonstrating steady business performance.","jir_summary":"### Overview of Business Performance\nIn the consolidated cumulative third quarter period of the fiscal year ending March 2026, Mochida Pharmaceutical Co., Ltd. reported net sales of \u00a587,487 million (up 8.4% YoY), operating income of \u00a57,526 million (up 3.9% YoY), ordinary income of \u00a58,346 million (up 9.2% YoY), and net income attributable to owners of parent of \u00a56,342 million (up 13.2% YoY). The pharmaceutical-related business saw increased sales year-over-year driven by growth in new drugs, while the healthcare business also posted an 8.2% increase in net sales. R&D expenses amounted to \u00a58,984 million, with ongoing development focused on nucleic acid and cell medicines.\n\n### Financial Position and Revision of Earnings Guidance\nTotal assets increased to \u00a5182,220 million compared to the end of the previous fiscal year, and net assets also rose to \u00a5137,431 million, while the equity ratio declined to 75.4%. The number of outstanding shares remained unchanged at 36,390,000 shares. The consolidated earnings forecast for the fiscal year ending March 2026 was revised to project net sales of \u00a5115,500 million (up 9.8% YoY), operating income of \u00a59,500 million (up 16.9% YoY), and net income attributable to owners of parent of \u00a58,400 million (up 47.8% YoY).","jir_financial_highlights":"Net Sales: \u00a587,487 million (Up 8.4% Year-over-Year)\nOperating Income: \u00a57,526 million (Up 3.9% Year-over-Year)\nOrdinary Income: \u00a58,346 million (Up 9.2% Year-over-Year)\nNet Income Attributable to Owners of Parent: \u00a56,342 million (Up 13.2% Year-over-Year)\nTotal Assets: \u00a5182,220 million (Increased by \u00a522,099 million from previous fiscal year-end)\nNet Assets: \u00a5137,431 million (Increased by \u00a56,737 million from previous fiscal year-end)\nEquity Ratio: 75.4% (Decreased Year-over-Year (81.6% \u2192 75.4%))\nNumber of Outstanding Shares (Common Stock): 36,390,000 shares (No change from previous period)\nTreasury Stock: 940,091 shares (Approximately flat compared to previous period)","jir_category":"","jir_hashtags":"#MochidaPharmaceutical, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a587,487 million (up 8.4% Year-over-Year)\nOperating Income: \u00a57,526 million (up 3.9% Year-over-Year)\nNet Income Attributable to Owners of Parent: \u00a56,342 million (up 13.2% Year-over-Year)","jir_meta_title":"Mochida Pharmaceutical 3Q FY2026 Earnings - Net Sales \u00a587,487 Million, Up 8.4% YoY","jir_meta_description":"Mochida Pharmaceutical Co., Ltd. announces its third quarter FY2026 consolidated financial summary, reporting net sales of \u00a587,487 million (up 8.4% YoY), operating income of \u00a57,526 million (up 3.9%), and net income of \u00a56,342 million (up 13.2%), reflecting solid performance.","jir_og_title":"Mochida Pharmaceutical 3Q FY2026 Earnings - Net Sales Increase of 8.4% to \u00a587,487 Million","jir_og_description":"Mochida Pharmaceutical's third quarter FY2026 consolidated financial summary reports steady growth with increases in revenue and profits.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"3Q FY2025\\\",\\\"3Q FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[80731,87487],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"3Q FY2025\\\",\\\"3Q FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[7243,7526],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"3Q FY2025\\\",\\\"3Q FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[5605,6342],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"major_products_sales\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Major Product Sales (Hundred Million Yen) Q3 Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Rialda\\\",\\\"Goofis\\\",\\\"Movicol\\\",\\\"Treprost\\\",\\\"Yulis\\\",\\\"Epader\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"3Q FY2025\\\",\\\"data\\\":[116,64,50,32,34,40],\\\"backgroundColor\\\":\\\"#59a14f\\\"},{\\\"label\\\":\\\"3Q FY2026\\\",\\\"data\\\":[126,69,56,46,47,35],\\\"backgroundColor\\\":\\\"#edc948\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Revenue Composition by Segment (3Q FY2026)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical-related Business\\\",\\\"Healthcare Business\\\"],\\\"datasets\\\":[{\\\"data\\\":[81533,5953],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\"]}]},\\\"options\\\":{}}\"}]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-25204","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n